• Mirum Pharmaceuticals recently reported new data from its rare liver disease programs at the EASL International Liver Congress 2026, including positive Phase 2b results for volixibat in primary sclerosing cholangitis and brelovitug in chronic hepatitis delta virus, as well as additional findings for LIVMARLI in progressive familial intrahepatic cholestasis.
• Together, these data points strengthen Mirum’s rare liver disease portfolio and suggest a broader clinical role for its bile acid–modulating therapies across multiple indications.
• Next, we’ll examine how the encouraging Phase 2b results for volixibat in primary sclerosing cholangitis shape Mirum Pharmaceuticals’ investment narrative.

Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

What Is Mirum Pharmaceuticals' Investment Narrative?

To own Mirum Pharmaceuticals, you have to believe its rare liver disease franchise can translate strong clinical execution into durable commercial uptake, despite sizable current losses and a relatively tight cash runway. The latest EASL data for volixibat in PSC, brelovitug in HDV and LIVMARLI in PFIC reinforce the idea that Mirum’s bile acid and virology platforms may support multiple indications, which matters because the key near term catalysts are now more clearly clustered around the planned volixibat NDA filing in H2 2026, pivotal HDV readouts and continued LIVMARLI label and geographic expansion. At the same time, the US$790.16 million Q1 loss, ongoing dilution and recent insider sales highlight that financing and execution risk remain front and center, even with a share price still well below consensus fair value estimates.

However, one risk around Mirum’s cash needs and potential future dilution is easy to overlook. Despite retreating, Mirum Pharmaceuticals' shares might still be trading above their fair value and there could be some more downside. Discover how much.

Exploring Other Perspectives

Three Simply Wall St Community fair value views span about US$95 to over US$414, underlining how far apart individual expectations sit. Against that wide spread, the recent EASL readouts and heavy current losses give you plenty of moving parts to weigh before deciding how Mirum might fit into your portfolio.

Explore 3 other fair value estimates on Mirum Pharmaceuticals - why the stock might be worth over 4x more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Mirum Pharmaceuticals research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Mirum Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Mirum Pharmaceuticals' overall financial health at a glance.

No Opportunity In Mirum Pharmaceuticals?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Capitalize on the AI infrastructure supercycle with our selection of the 47 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Outshine the giants: these 12 early-stage AI stocks could fund your retirement.
• The latest GPUs need a type of rare earth metal called Dysprosium and there are only 31 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.